HealthTree Podcast for AML: Eytan Stein, MD, Memorial Sloan Kettering
The IDH mutation can be found in approximately 20% of adult AML cases. Isocitrate dehydrogenase isoform 1 and 2 or IDH1 and IDH2 mutations are typically found in older AML patients and have an interme...
24 Aug 202258min
Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale
The TP53 mutation in AML is considered to be a high risk mutation and occurs in approximately 5-10% of patients. This genetic mutation has been difficult to treat, often being chemoresistant with a po...
14 Juli 20221h 1min
HealthTree Podcast for AML: Dr. Jane Liesveld, University of Rochester
The FLT3 gene mutation is the most common mutation seen in acute myeloid leukemia patients. It occurs in up to 37% of adult patients with AML. FLT3 mutations have been harder to treat with poor outcom...
29 Juni 20221h
HealthTree Podcast for AML: Dr. Kendra Sweet, Moffitt Cancer Center
Immunotherapy continues to be an expanding and evolving area of research for AML with many drugs in development. One drug currently being studied is IMGN632, an antibody drug conjugate, that targets C...
9 Juni 202258min
HealthTree Podcast for AML: Dr. Joseph Jurcic, Columbia University
Immunotherapy is one of the most promising areas of cancer research. Drugs like checkpoint inhibitors, monoclonal and bispecific anitbodies, antibody drug conjugates and CAR-T cell therapy are all ext...
26 Maj 20221h 1min
HealthTree Radio for AML: Margaret Kasner, MD, Thomas Jefferson University
About 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several d...
7 Feb 202256min
HealthTree Radio for AML: Eytan Stein, MD, Memorial Sloan Kettering
There is a tremendous amount of progress being made in AML. It was remarkable to see the significant work being done in the field of AML at the recent American Society of Hematology (ASH) conference i...
2 Feb 20221h 5min
